Image taken at the UEB AICA production plant, belonging to the AICA Laboratories Company, where Abdala’s production scaling takes place. Photo: Ricardo López Hevia / Granma.
–
Cuba sent Venezuela a batch of Abdala, the first vaccine against Covid-19 developed and produced in Latin America with an efficacy of 92.28 percent, as reported this Saturday by the Center for Genetic Engineering and Biotechnology of the Caribbean nation.
In its Twitter account, the CIGB confirmed, without specifying the amount, the transfer to the Bolivarian nation of the drug, designed by that scientific center and which showed 90 percent effectiveness in critically ill patients and against the Delta variant of Covid-19 .
Abdala presented these results with a three-dose schedule at zero, 14, and 28-day intervals.
The CIGB confirmed this Saturday the production of 30 million units of the injectable to guarantee the immunization of the Cuban population over 19 years of age, which includes pregnant women, nursing mothers, people with transplants, adolescents and young people in terminal grades of the national education system. .
In the same social network, the entity reported the day before about the delivery of 120 thousand doses without thiomersal that allowed to start this day in the capital and in other provinces of the island with the vaccination of people allergic to this component.
According to the Cuban Ministry of Public Health, thimerosal or thimerosal was previously used to heal wounds and is present in many of the country’s vaccines.
In the case of multi-dose batches of Cuban immunogens, this compound functions as a preservative of the product, hence the need to produce single-dose batches to dispense with the substance.
(Taken from The Day)
– .
